Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nutriband Inc.

6.68
+1.0017.61%
Volume:387.48K
Turnover:2.75M
Market Cap:74.19M
PE:-6.75
High:8.11
Open:7.10
Low:6.45
Close:5.68
Loading ...

Company Profile

Company Name:
Nutriband Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
- -
Office Location:
121 South Orange Avenue,Suite 1500,Orlando,Florida,United States
Zip Code:
32801
Fax:
- -
Introduction:
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Directors

Name
Position
Gareth Sheridan
Chief Executive Officer and Director
Serguei Melnik
Chairman of the Board, President and Secretary
Irina Gram
Director
Mark Hamilton
Director
Radu Bujoreanu
Director
Stefan Mancas
Director

Shareholders

Name
Position
Gareth Sheridan
Chief Executive Officer and Director
Gerald Goodman
Chief Financial Officer
Alan Smith
Chief operating officer
Jeff Patrick
Chief scientific officer
Patrick Ryan
Chief technical officer
Serguei Melnik
Chairman of the Board, President and Secretary